Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

Pfizer has gained accelerated approval from the US FDA for BRAFTOVI in conjunction with cetuximab and mFOLFOX6 for treating mCRC.

Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs).

Palleon and Henlius Biotech have entered into a licence agreement and partnership for the former’s E-602 to treat autoimmune diseases.

The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.

The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS ...

Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.

Abera and Orexo have entered a partnership to develop and test the powder formulations of the former’s vaccine candidates.

The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 2024–2028 VPAG.

Gilead Sciences has entered a strategic partnership with Terray for the discovery and development of small-molecule therapies.